The ATLANTIC study assessed the effect of durvalumab treatment in three cohorts of patients with NSCLC defined by EGFR/anaplastic lymphoma kinase status and tumor expression of PD-L1 [69]. The gene discussed is EGFR; the disease is neoplasm.